Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001785530-23-000033
Filing Date
2023-11-14
Accepted
2023-11-14 16:20:39
Documents
63
Period of Report
2023-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q howl-20230930.htm   iXBRL 10-Q 1401991
2 EX-31.1 a09302023ex311.htm EX-31.1 10340
3 EX-31.2 a09302023ex312.htm EX-31.2 10364
4 EX-32.1 a09302023ex321.htm EX-32.1 7042
  Complete submission text file 0001785530-23-000033.txt   5432276

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT howl-20230930.xsd EX-101.SCH 34547
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT howl-20230930_cal.xml EX-101.CAL 48098
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT howl-20230930_def.xml EX-101.DEF 188701
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT howl-20230930_lab.xml EX-101.LAB 447658
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT howl-20230930_pre.xml EX-101.PRE 323404
57 EXTRACTED XBRL INSTANCE DOCUMENT howl-20230930_htm.xml XML 555870
Mailing Address 200 TALCOTT AVENUE 2ND FLOOR WATERTOWN MA 02472
Business Address 200 TALCOTT AVENUE 2ND FLOOR WATERTOWN MA 02472 617-952-0555
Werewolf Therapeutics, Inc. (Filer) CIK: 0001785530 (see all company filings)

EIN.: 823523180 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40366 | Film No.: 231406690
SIC: 2834 Pharmaceutical Preparations